Prospective randomized study of tolerability and efficacy of combination therapy on chronic kidney disease

INTERVENTION: Loosartan and hydrochlorothiazide group Loosartan and enalapril group Loosartan and amlodipine group CONDITION: Chronic kidney diseases PRIMARY OUTCOME: Blood pressure changes at 4 months after the start of combination therapy SECONDARY OUTCOME: Changes in systolic blood pressure at 4 months after the start of combination therapy; Rates of systolic blood pressure change and achievement of goal systolic blood pressure at 4 months after the start of combination therapy; Rates of changes in urinary excretion of protein or albumin at 4 months after the start of combination therapy; Rates and values of systolic blood pressure at 12 months after the start of combination therapy; Rates of changes in urinary excretion of protein or albumin at 12 months after the start of combination therapy; Changes in eGFR values at 12 months after the start of combination therapy; Rates of achievement of goal blood pressure 12 months after the start of combination therapy; Changes in HOMA‐R; Safety of the drugs throughout the study period INCLUSION CRITERIA: 1) At 2 months after the therapy with 50 mg of losartan, systolic blood pressure is more than 130 mmHg and/or diastolic blood pressure is more than 80 mmHg. 2) Outpatients only 3) Written informed consent is required.